Five days of AB-FUBINACA administration in mice caused significant kidney damage through oxidative stress, inflammation, and mitochondrial dysfunction, providing mechanistic evidence for synthetic cannabinoid-induced kidney injury.
Toxicologists, nephrologists, emergency medicine physicians, synthetic cannabinoid researchers
Mitochondrial complexes I, III, and IV reduced in kidney tissue
What the researchers found
AB-FUBINACA (3 mg/kg for 5 days) induced substantial renal function impairment with elevated kidney damage markers KIM-1 and NGAL. The mechanism involved increased oxidative stress markers (iNOS, NOX4, NOX2, NOS3) and lipid peroxidation, enhanced pro-inflammatory markers (IL-6, TNF-alpha, NF-kB), and activation of caspase-dependent apoptosis (Bax, caspase-9, caspase-3). Mitochondrial complexes I, III, and IV were reduced, suggesting mitochondrial dysfunction underlies the nephrotoxicity.
Why it matters
Synthetic cannabinoid-induced acute kidney injury is increasingly reported but poorly understood. This study identifies a specific mechanism linking mitochondrial dysfunction to oxidative stress, inflammation, and cell death in the kidney, which could inform treatment approaches.
The numbers in context
AB-FUBINACA 3 mg/kg for 5 days; elevated KIM-1 and NGAL; increased iNOS, NOX4, NOX2, NOS3; increased IL-6, TNF-alpha, NF-kB; activated Bax, caspase-9, caspase-3; reduced mitochondrial complexes I, III, IV
How the study worked
Mouse study investigating nephrotoxic effects of acute AB-FUBINACA administration (3 mg/kg for 5 days). Measured oxidative stress, inflammation, and apoptosis markers. Assessed mitochondrial complex (I-V) expression in renal tissues.
What this study cannot tell us
Mouse model with acute high-dose exposure may not reflect typical human use patterns. Single synthetic cannabinoid tested; results may not generalize to other compounds. Short 5-day exposure does not address chronic effects. Mouse-to-human dose translation is uncertain.
How to read the evidence
Well-designed mechanistic animal study with comprehensive biomarker analysis, but single compound tested and mouse model limitations reduce translational confidence.
When this study was published
2025 publication
The bigger picture
Synthetic cannabinoids represent a fundamentally different risk profile from natural cannabis. Understanding the specific organ damage mechanisms helps explain why synthetic cannabinoid emergencies are so much more severe than natural cannabis reactions and guides clinical management.
Questions still open
- Could antioxidants or mitochondrial-targeted therapies prevent or treat synthetic cannabinoid nephrotoxicity? Do other synthetic cannabinoids produce similar kidney damage through the same mechanism?
Common questions
How do synthetic cannabinoids damage the kidneys?
Is this the same risk as with natural cannabis?
Read the original research
In vivo assessment of the nephrotoxic effects of the synthetic cannabinoid AB-FUBINACA.
Forensic toxicology, 43(1), 86-96
Citation
Alzu'bi, Ayman; Abu-El-Rub, Ejlal; Al-Trad, Bahaa; Alzoubi, Hiba; Abu-El-Rub, Hadeel; Albals, Dima; Abdelhady, Gamal T; Bader, Noor S; Almazari, Rawan; Al-Zoubi, Raed M. (2025). In vivo assessment of the nephrotoxic effects of the synthetic cannabinoid AB-FUBINACA.. Forensic toxicology, 43(1), 86-96. https://doi.org/10.1007/s11419-024-00699-9